Hornung R S, Hillis W S
Br J Clin Pharmacol. 1987 Jan;23(1):29-33. doi: 10.1111/j.1365-2125.1987.tb03005.x.
Intravenous enalaprilic acid (2.5 mg) was given to 11 patients with stable cardiac failure (NYHA functional class II-IV). Reductions in mean right atrial, pulmonary artery and pulmonary capillary wedge pressure of 25%, 18% and 30% respectively (P less than 0.01), were observed. Cardiac output rose by 13% (NS) and mean blood pressure fell by 20% (P less than 0.01) with a decrease in systemic vascular resistance of 24% (P less than 0.01). Heart rate was unaltered. The haemodynamic effects correlated with control plasma renin activity (r = 0.78, P less than 0.01). Marked hypotension occurred in several subjects but no other side-effects were noted. The rapid onset of action and mixed venous and arteriolar dilating activity of intravenous enalaprilic acid may be an advantage in some clinical situations where parenteral vasodilating therapy is required.
对11例稳定型心力衰竭（纽约心脏协会心功能分级II - IV级）患者静脉注射依那普利酸（2.5毫克）。观察到平均右心房压、肺动脉压和肺毛细血管楔压分别降低25%、18%和30%（P < 0.01）。心输出量增加13%（无统计学意义），平均血压下降20%（P < 0.01），全身血管阻力降低24%（P < 0.01）。心率未改变。血流动力学效应与对照血浆肾素活性相关（r = 0.78，P < 0.01）。几名受试者出现明显低血压，但未观察到其他副作用。静脉注射依那普利酸起效迅速，具有混合静脉和小动脉扩张活性，在某些需要胃肠外血管扩张治疗的临床情况下可能具有优势。
